Brain drug targeting and gene technologies

Japanese Journal of Pharmacology

Volumn 87, Issue 2, 2001, Pages 97-103

  Pardridge, W M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Blood brain barrier; Brain derived neurotrophic factor; Epidermal growth factor; Gene therapy; Genomics

Indexed keywords

ANTIBODY CONJUGATE; AVIDIN; BIOTIN; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR MACROGOL 2000 BIOTIN OX26 STREPTAVIDIN CONJUGATE; BRAIN DERIVED NEUROTROPHIC FACTOR MONOCLONAL ANTIBODY CONJUGATE; BRAIN DERIVED NEUROTROPHIC FACTOR OX26 MONOCLONAL ANTIBODY CONJUGATE; CHIMERIC PROTEIN; DRUG CARRIER; EPIDERMAL GROWTH FACTOR; HUMAN INSULIN RECEPTOR MONOCLONAL ANTIBODY; HUMAN MONOCLONAL ANTIBODY; IMMUNOLIPOSOME; INDIUM 111; INSULIN RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY 83 14; MONOCLONAL ANTIBODY 8D3; MONOCLONAL ANTIBODY OX26; MONOCLONAL ANTIBODY OX26 CONJUGATE; NEUROTROPHIN; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; OX26 STREPTAVIDIN CONJUGATE; PENTETATE EPIDERMAL GROWTH FACTOR MACROGOL 3400 BIOTIN IN 111; PENTETATE INDIUM IN 111; PEPTIDE NUCLEIC ACID; RADIOPHARMACEUTICAL AGENT; STREPTAVIDIN; STREPTAVIDIN MONOCLONAL ANTIBODY CONJUGATE; TRANSFERRIN RECEPTOR MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACTIVE TRANSPORT; BLOOD BRAIN BARRIER; BRAIN CANCER; BRAIN DISEASE; BRAIN PROTECTION; BRAIN RADIOGRAPHY; CENTRAL NERVOUS SYSTEM; DISEASE MODEL; DNA VECTOR; DRUG DELIVERY SYSTEM; DRUG TARGETING; GENE EXPRESSION; GENE TARGETING; GENE TECHNOLOGY; GENE THERAPY; GENETIC ENGINEERING; IMMUNOGENICITY; IN VIVO STUDY; MOLECULE; NONHUMAN; REVIEW; STROKE; TRANSCYTOSIS;

EID: 0034756894     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.87.97     Document Type: Review

References (25)

1. Drug discovery: A historical perspective
2. Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor
3. An anti-transferrin receptor antibody-avidin fusion protein serves as a delivery vehicle for effective brain targeting in an animal model. Initial applications in antisense drug delivery to the brain
4. Genetically engineered brain drug delivery vectors - Cloning, expression, and in vivo application of an anti-transferrin receptor single chain antibody-streptavidin fusion gene and protein
5. Human insulin receptor monoclonal antibody undergoes high affinity bindiong to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate
6. 111In chelation, conjugation to a blood-brain barrier delivery vector via a biotin-polyethylene linker, pharmacokinetics, and in vivo imaging of experimental brain tumors
7. Imaging brain tumors by targeting peptide radiopharmaceuticals through the blood-brain barrier
8. Mediated efflux of IgG molecules from brain to blood across the blood-brain barrier
9. Carboxyl-directed pegylation of brain-derived neurotrophic factor markedly reduces systemic clearance with minimal loss of biologic activity
10. Conjugation of brain-derived neurotrophic factor to a blood-brain barrier drug targeting system enables neuroprotection in regional brain ischemia following intravenous injection of the neurotrophin
11. Neuroprotection in transient focal brain ischemia following delayed, intravenous administration of BDNF conjugated to a blood-brain barrier drug targeting system
12. Neuroprotection with non-invasive neurotrophin delivery to brain
13. Antisense imaging of gene expression in the brain in vivo
14. Non-invasive gene targeting to the brain
15. Expression of the neuronal transferrin receptor is age dependent and susceptible to iron deficiency
16. P-glycoprotein-mediated efflux transport of anticancer drugs at the blood-brain barrier
17. Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier
18. Development of brain efflux index (BEI) method and its application to the blood-brain barrier efflux transport study
19. Blood-brain barrier genomics
20. The impact of genomic's technologies on pharmaceutical research
21. Quantitative monitoring of gene expression patterns with a complementary DNA microarray
22. Suppression subtractive hybridization: A method for generating defferentially regulated or tissue-specific cDNA probes and libraries
23. Retention of biologic activity of human epidermal growth factor following conjugation to a blood-brain barrier drug delivery vector via an extended polyethyleneglycol linker